.PDF | .DOC
Printable Version of RFP (.pdf)
Muscular Dystrophy Canada is a national, non-profit organization of dedicated volunteers and staff who continually work to provide support and resources to people impacted by neuromuscular disorders, and fund high-quality research striving to find better treatments, and a cure as soon as possible. We cover over 150 different types of neuromuscular disorders.
Respiratory health is a priority issue for people affected by neuromuscular disorders. Since 2012, Muscular Dystrophy Canada has focused on identifying the problems, gaps and opportunities to enhance education, awareness, clinical care, and research with respect to Respiratory Care.
The intent of this request is to solicit proposals related to improving respiratory health for people living with neuromuscular diseases. Projects should be carried out within a 12-month framework (beginning November 2016 or from date that ethics approval is obtained, if required), and have a budget between $25,000 – $50,000.
Many types of neuromuscular disorders have a progressive impact on the muscles required for airway clearance and good respiratory function. Respiratory care has a significant impact on the quality of life and longevity of many patients with a neuromuscular condition. For instance, respiratory failure is the number one cause of death among people with Duchenne muscular dystrophy, yet today there are preventative measures and interventions that can be beneficial in maintaining and prolonging comfort of life.
There are significant differences in government programs that provide access to ventilation supports, care and services across Canada. Many people who rely on invasive mechanical ventilation are unable to live in the community due to high costs and high care needs, and in these situations, individuals often unnecessarily reside in ICU or Long Term Care institutions. Prevention of secondary complex medical conditions is critical in order to prevent long term hospital admissions, loss of independence or life threatening conditions. Non-invasive ventilation, which poses a decreased risk of infection, is not universally accepted as the standard of care. Patients and health care providers both need to increase their awareness and understanding of ventilation options.
The objectives of this initiative are to:
Lead applicants must hold an affiliation with a Canadian or international recognized academic institution. Eligible research institutions include those that are accepted under CIHR’s grant policies. Other institutions, including those outside of Canada, will be considered on an ad hoc basis as part of the peer review process, and may be required to provide additional documentation to support the application.
Private corporate entities are not eligible for funding.
Muscular Dystrophy Canada has committed $150,000 to support the successful research projects. The maximum budget per project is $50,000. It is estimated that 3-5 proposals will be awarded funding.
Projects must be directly relevant to respiratory health for people with neuromuscular disorders (applications not meeting this criterion will not be reviewed). This includes:
Proposals for knowledge translation projects must include a clearly defined assessment component.
Basic science projects would be considered out of scope.
Allowable expenses include:
Indirect expenses (i.e. payments towards general institutional overhead) are ineligible and therefore must be excluded from the budget.
Applications will be awarded through a competitive peer-review process. Proposals will be reviewed by Muscular Dystrophy’s Medical Science and Advisory Committee. Members will declare any conflict of interest with any application and excuse themselves from its review. Additional external expertise may be sought to enhance the review process (i.e., when gaps in expertise is noted or another opinion is beneficial or there is a conflict of interest).
Proposals will be reviewed taking into consideration factors including:
Send the completed application form to Research@muscle.ca by Thursday June 30, 2016, 11:59 pm (EDT). In the body of the email, please include the title of the project, your contact details, and a list of attachments.
All submissions will receive an email acknowledgement upon receipt.
Contact: Catherine Willinsky
Acting Director of Research, Muscular Dystrophy Canada.
Tel: 416-488-0030 ext 1103